Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552041 | 1.00 | NPSR1 (0.42) | NPSR1SMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL1729385 | 1.00 | NPSR1 (0.42) | NPSR1SMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL15701448 | 0.83 | HTT (0.39) | NPSR1SMN1; SMN2ALDH1A1HTTHPGD | |
| SCHEMBL4745432 | 0.83 | CTSS (0.39) | HTTCTSSCTSK | |
| SCHEMBL13192726 | 0.83 | HTT (0.38) | SMN1; SMN2HTTHPGDTSHRCTSS | |
| SCHEMBL12631270 | 0.83 | TSHR (0.42) | SMN1; SMN2ALDH1A1HTTHPGDTSHR | |
| SCHEMBL10441262 | 0.83 | TSHR (0.42) | SMN1; SMN2ALDH1A1HTTHPGDTSHR | |
| SCHEMBL10442172 | 0.82 | ALDH1A1 (0.43) | NPSR1SMN1; SMN2ALDH1A1HTTPLA2G2A | |
| SCHEMBL191467 | 0.82 | SMN1; SMN2 (0.44) | NPSR1SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL4994 | 0.82 | SMN1; SMN2 (0.44) | NPSR1SMN1; SMN2ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5453531-A | Insecticides, fungicides for plants | BAYER AKTIENGESELLSCHAFT (DE) | 1995-09-26 | — | — | US | claimed |
| EP-0472996-B1 | Substituted valinamide derivatives | BAYER AG (DE) | 1995-02-01 | — | — | EP | claimed |
| EP-0550788-A1 | Substituted valinamide derivatives | BAYER AG (DE) | 1993-07-14 | — | — | EP | claimed |
| EP-0472996-A1 | Substituted valinamide derivatives | BAYER AG (DE) | 1992-03-04 | — | — | EP | claimed |
| EP-2621279-B1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9447055-B1 | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | MERCK SERONO S.A. (CH) | 2016-09-20 | — | — | US | disclosed |
| US-9254292-B2 | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-09 | — | — | US | disclosed |
| US-8980920-B2 | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-0587110-A2 | Condensed heterocyclic derivatives and agricultural or horticultural fungicides containing the same | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0550788-A1 | Substituted valinamide derivatives | BAYER AG (DE) | 1993-07-14 | — | — | EP | disclosed |
| WO-1993005026-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
| EP-0496239-A2 | Substituted aminoacid amide derivatives, their preparation and use as fungicide | BAYER AG (DE) | 1992-07-29 | — | — | EP | disclosed |
| EP-0472996-A1 | Substituted valinamide derivatives | BAYER AG (DE) | 1992-03-04 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | NPSR1 4039/4885SMN1; SMN2 957/4885ALDH1A1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.